Non-Cystic Fibrosis Bronchiectasis ʻO ka hoʻāʻo lāʻau lapaʻau hou

ʻO Armata Pharmaceuticals, Inc., kahi hui biotechnology e kālele ana i nā lāʻau lapaʻau bacteriophage pathogen-specific no nā maʻi bacterial-kūʻokoʻa a paʻakikī hoʻi i ka mālama ʻana, i kēia lā ua hoʻolaha ka US Food and Drug Administration (FDA) i kā Armata's Investigational New Drug (IND) noi e hoʻomaka i kahi hoʻokolohua lapaʻau o kāna moho lāʻau lapaʻau alakaʻi maikaʻi loa, AP-PA02, ma kahi hōʻailona ʻelua, non-cystic fibrosis bronchiectasis (NCFB). Hoʻolālā ka hui e hoʻomaka i kahi hoʻokolohua Phase 2 ma 2022.     

I nā poʻe maʻi me ka NCFB, pili pinepine ka maʻi māmā me Pseudomonas aeruginosa me ka hoʻonui pinepine ʻana i ka pulmonary exacerbations, hoʻemi ʻia ka maikaʻi o ke ola, a me ka piʻi ʻana o ka make, a pono paha ke komo i ka haukapila no ka mālama ʻana. ʻOiai ua ʻōlelo ʻia nā lāʻau antibiotic inhaled mau no ka hoʻokele lōʻihi o ka NCFB me nā exacerbations pinepine, ʻaʻohe lāʻau lapaʻau i ʻae ʻia.

"ʻOliʻoli mākou i ka loaʻa ʻana o ka ʻae FDA e holomua i ka AP-PA02 i ka hōʻailona hanu lua," wahi a Brian Varnum, Luna Nui o Armata. "Me kēia ʻae hoʻoponopono a me kā mākou kālā kālā hou, ua kūpono mākou e ʻimi i ka pono lapaʻau o AP-PA02, a e holomua i ka AP-SA02 no nā maʻi hui prosthetic a me AP-PA03 no ka pneumonia."      

Ma waho aʻe o ka hoʻokolokolo e hiki mai ana o AP-PA02 ma NCFB, ke alakaʻi nei ʻo Armata i kahi hoʻokolokolo Phase 1b/2a ('SWARM-Pa') o AP-PA02 e kuhikuhi ana i nā maʻi Pseudomonas aeruginosa i nā maʻi cystic fibrosis, a me kahi hoʻāʻo Phase 1b/2a. ('diSArm') o AP-SA02 e huli ana iā Staphylococcus aureus bacteremia.